11 results on '"Hensey, Mark"'
Search Results
2. The Wattson temporary pacing guidewire for transcatheter heart valve implantation.
- Author
-
Carey J, Buckley A, O'Connor S, and Hensey M
- Subjects
- Aortic Valve surgery, Cardiac Pacing, Artificial, Humans, Treatment Outcome, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Pacemaker, Artificial, Transcatheter Aortic Valve Replacement methods
- Abstract
Transcatheter aortic valve implantation and implantation of other transcatheter heart valves, generally requires insertion of a temporary venous pacemaker. Implantation of a temporary venous pacemaker adds complexity, time and risk to the procedure. Guidewire modification to allow pacing is increasingly popular, however it requires technical expertise and provides unipolar pacing resulting in high thresholds and potential capture loss. The Wattson temporary pacing guidewire is a novel device which offers guidewire support for valve delivery and concomitant bipolar pacing. It may offer a safe and effective solution to guidewire pacing for transcatheter aortic valve implantation and other transcatheter heart valve implantations. Herein, we review the literature surrounding left ventricular guidewire pacing along with the features and clinical data of the Wattson wire.
- Published
- 2022
- Full Text
- View/download PDF
3. Single-center prospective study examining use of the Wattson temporary pacing guidewire for transcatheter aortic valve replacement.
- Author
-
Hensey M, Sathananthan J, Alkhodair A, Landes U, Wood DA, Daniels D, and Webb JG
- Subjects
- Aged, Aged, 80 and over, Aortic Valve diagnostic imaging, Aortic Valve physiopathology, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis physiopathology, Equipment Design, Female, Humans, Male, Prospective Studies, Time Factors, Treatment Outcome, Aortic Valve surgery, Aortic Valve Stenosis surgery, Cardiac Catheters, Cardiac Pacing, Artificial, Pacemaker, Artificial, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Objectives: To assess the safety and efficacy of the Wattson temporary pacing guidewire., Background: Transcatheter aortic valve replacement (TAVR) requires a guidewire for device delivery and generally requires temporary pacing wire for burst and back-up pacing. The Wattson wire provides concomitant support and bipolar pacing without the need to place a temporary venous pacemaker (TVP)., Methods: This was a single-center nonrandomized prospective clinical trial enrolling 20 patients. The primary endpoint was defined as successful rapid pacing and transcatheter heart valve (THV) delivery with no loss of capture. Safety, qualitative and quantitative secondary outcomes were also analyzed., Results: Mean age was 77.4 ± 9.0 years. Mean Society of Thoracic Surgery (STS) score was 3.0 ± 1.5%. All patients received a balloon-expandable valve via a transfemoral approach. All patients met the primary end-point. One patient (5%) had balloon predilatation and six patients (30%) had postdilatation, all using the wire. Mean pacing threshold was 2.2 ± 1.2 mA that was evaluated prior to placing an insulating catheter over the wire. One patient required TVP placement and subsequent permanent pacemaker implantation due to complete heart block post THV deployment. There were no incidences of cardiac perforation or tamponade. One patient required valve reintervention, which was not related to the device., Conclusions: The Wattson wire offered predictable guidewire support with concomitant reliable bipolar pacing at low thresholds to allow safe THV delivery in this patient cohort. It has the potential to make TAVR a safer and more efficient procedure., (© 2020 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
4. Mitral regurgitation in patients undergoing transcatheter aortic valve implantation for degenerated surgical aortic bioprosthesis: Insights from PARTNER 2 Valve-in-Valve Registry.
- Author
-
Murdoch DJ, Sathananthan J, Hensey M, Alu MC, Liu Y, Crowley A, Wood D, Cheung A, Ye J, Feldman T, Hahn RT, Jaber WA, Mack MJ, Malaisrie SC, Leon MB, and Webb JG
- Subjects
- Aged, Aged, 80 and over, Aortic Valve diagnostic imaging, Aortic Valve physiopathology, Aortic Valve Insufficiency diagnostic imaging, Aortic Valve Insufficiency mortality, Aortic Valve Insufficiency physiopathology, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis mortality, Aortic Valve Stenosis physiopathology, Female, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation mortality, Humans, Male, Mitral Valve diagnostic imaging, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency mortality, Recovery of Function, Registries, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Aortic Valve surgery, Aortic Valve Insufficiency surgery, Aortic Valve Stenosis surgery, Bioprosthesis, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation instrumentation, Mitral Valve physiopathology, Mitral Valve Insufficiency physiopathology, Prosthesis Failure, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement instrumentation, Transcatheter Aortic Valve Replacement mortality
- Abstract
Background: Valve-in-valve (VIV) treatment with transcatheter aortic valve replacement (TAVR) is a viable option for patients with failing aortic bioprosthetic valves. Optimal management of those with concomitant mitral regurgitation (MR) remains undetermined. Therefore, we sought to assess the implications of concomitant MR in patients undergoing VIV-TAVR., Methods and Results: The PARTNER 2 VIV registry enrolled patients with degenerated surgical aortic bioprosthesis at high risk for reoperation. Patients with core-laboratory echocardiographic assessment of MR were analyzed; severe MR was excluded. We compared patients with ≤mild MR versus moderate MR and assessed changes in MR severity and clinical outcomes. A total of 339 patients (89 initial registry, 250 continued access) underwent VIV procedures; mean age 79.0 ± 10.2 years, mean Society of Thoracic Surgeon score 8.9 ± 4.5%. At baseline, 228/339 (67.3%) had ≤mild MR and 111/339 (32.7%) had moderate MR. In paired analysis, there was significant improvement in ≥moderate MR from baseline to 30 days (32.6% vs. 14.5%, p < .0001 [n = 304]), and no significant change between 30 days and 1 year (13.4% vs. 12.1%, p = .56 [n = 224]) or 1 year and 2 years (11.0% vs. 10.4%, p = .81 [n = 182]). There was no difference in death or stroke between ≤mild MR and moderate MR at 30 days (4.0% vs. 7.2%, p = .20), 1 year (15.5% vs. 15.3%, p = .98) or 2 years (26.5% vs. 23.5%, p = .67)., Conclusion: Moderate concomitant MR tends to improve with VIV-TAVR, and was not a predictor of long-term adverse outcomes in this cohort. In selected patients undergoing VIV-TAVR, it may be appropriate to conservatively manage concomitant MR., Clinical Trial Registration: ClinicalTrials.gov NCT# 03225001., (© 2020 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
5. Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction.
- Author
-
Landes U, Webb JG, De Backer O, Sondergaard L, Abdel-Wahab M, Crusius L, Kim WK, Hamm C, Buzzatti N, Montorfano M, Ludwig S, Schofer N, Voigtlaender L, Guerrero M, El Sabbagh A, Rodés-Cabau J, Guimaraes L, Kornowski R, Codner P, Okuno T, Pilgrim T, Fiorina C, Colombo A, Mangieri A, Eltchaninoff H, Nombela-Franco L, Van Wiechen MPH, Van Mieghem NM, Tchétché D, Schoels WH, Kullmer M, Tamburino C, Sinning JM, Al-Kassou B, Perlman GY, Danenberg H, Ielasi A, Fraccaro C, Tarantini G, De Marco F, Witberg G, Redwood SR, Lisko JC, Babaliaros VC, Laine M, Nerla R, Castriota F, Finkelstein A, Loewenstein I, Eitan A, Jaffe R, Ruile P, Neumann FJ, Piazza N, Alosaimi H, Sievert H, Sievert K, Russo M, Andreas M, Bunc M, Latib A, Govdfrey R, Hildick-Smith D, Sathananthan J, Hensey M, Alkhodair A, Blanke P, Leipsic J, Wood DA, Nazif TM, Kodali S, Leon MB, and Barbanti M
- Subjects
- Aged, Aortic Valve surgery, Equipment Failure Analysis, Female, Global Health, Humans, Male, Outcome Assessment, Health Care, Registries statistics & numerical data, Survival Analysis, Symptom Assessment statistics & numerical data, Aortic Valve Insufficiency diagnosis, Aortic Valve Insufficiency epidemiology, Aortic Valve Insufficiency etiology, Aortic Valve Insufficiency surgery, Aortic Valve Stenosis surgery, Heart Valve Prosthesis adverse effects, Postoperative Complications diagnosis, Postoperative Complications epidemiology, Postoperative Complications surgery, Reoperation instrumentation, Reoperation methods, Reoperation statistics & numerical data, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement instrumentation, Transcatheter Aortic Valve Replacement methods
- Abstract
Background: Transcatheter aortic valve replacement (TAVR) use is increasing in patients with longer life expectancy, yet robust data on the durability of transcatheter heart valves (THVs) are limited. Redo-TAVR may play a key strategy in treating patients in whom THVs fail., Objectives: The authors sought to examine outcomes following redo-TAVR., Methods: The Redo-TAVR registry collected data on consecutive patients who underwent redo-TAVR at 37 centers. Patients were classified as probable TAVR failure or probable THV failure if they presented within or beyond 1 year of their index TAVR, respectively., Results: Among 63,876 TAVR procedures, 212 consecutive redo-TAVR procedures were identified (0.33%): 74 within and 138 beyond 1 year of the initial procedure. For these 2 groups, TAVR-to-redo-TAVR time was 68 (38 to 154) days and 5 (3 to 6) years. The indication for redo-TAVR was THV stenosis in 12 (16.2%) and 51 (37.0%) (p = 0.002) and regurgitation or combined stenosis-regurgitation in 62 (83.8%) and 86 (62.3%) (p = 0.028), respectively. Device success using VARC-2 criteria was achieved in 180 patients (85.1%); most failures were attributable to high residual gradients (14.1%) or regurgitation (8.9%). At 30-day and 1-year follow-up, residual gradients were 12.6 ± 7.5 mm Hg and 12.9 ± 9.0 mm Hg; valve area 1.63 ± 0.61 cm
2 and 1.51 ± 0.57 cm2 ; and regurgitation ≤mild in 91% and 91%, respectively. Peri-procedural complication rates were low (3 stroke [1.4%], 7 valve malposition [3.3%], 2 coronary obstruction [0.9%], 20 new permanent pacemaker [9.6%], no mortality), and symptomatic improvement was substantial. Survival at 30 days was 94.6% and 98.5% (p = 0.101) and 83.6% and 88.3% (p = 0.335) at 1 year for patients presenting with early and late valve dysfunction, respectively., Conclusions: Redo-TAVR is a relatively safe and effective option for selected patients with valve dysfunction after TAVR. These results are important for applicability of TAVR in patients with long life expectancy in whom THV durability may be a concern., (Copyright © 2020. Published by Elsevier Inc.)- Published
- 2020
- Full Text
- View/download PDF
6. Mid-Term Outcomes of Transcatheter Aortic Valve Replacement in Extremely Large Annuli With Edwards SAPIEN 3 Valve.
- Author
-
Sengupta A, Zaid S, Kamioka N, Terre J, Miyasaka M, Hirji SA, Hensey M, Geloo N, Petrossian G, Robinson N, Sarin E, Ryan L, Yoon SH, Tan CW, Khalique OK, Kodali SK, Kaneko T, Shah PB, Wong SC, Salemi A, Sharma K, Kozina JA, Szerlip MA, Don CW, Gafoor S, Zhang M, Newhart Z, Kapadia SR, Mick SL, Krishnaswamy A, Kini A, Ahmad H, Lansman SL, Mack MJ, Webb JG, Babaliaros V, Thourani VH, Makkar RR, Leon MB, George I, and Tang GHL
- Subjects
- Aged, Aged, 80 and over, Aortic Valve diagnostic imaging, Aortic Valve physiopathology, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis mortality, Aortic Valve Stenosis physiopathology, Female, Hemodynamics, Humans, Male, North America, Postoperative Complications mortality, Postoperative Complications therapy, Recovery of Function, Retrospective Studies, Risk Factors, Severity of Illness Index, Time Factors, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement mortality, Treatment Outcome, Aortic Valve surgery, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Prosthesis Design, Transcatheter Aortic Valve Replacement instrumentation
- Abstract
Objectives: The aim of this study was to report the 1-year results of transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 (S3) valve in extremely large annuli., Background: Favorable 30-day outcomes of S3 TAVR in annuli >683 mm
2 have previously been reported. Pacemaker implantation rates were acceptable, and a larger left ventricular outflow tract and more eccentric annular anatomy were associated with increasing paravalvular leak., Methods: From December 2013 to December 2018, 105 patients across 15 centers with mean area 721.3 ± 36.1 mm2 (range 683.5 to 852.0 mm2 ) underwent TAVR using an S3 device. Clinical, anatomic, and procedural characteristics were analyzed. One-year survival and echocardiographic follow-up were reached in 94.3% and 82.1% of patients, respectively. Valve Academic Research Consortium-2 30-day and 1-year outcomes were reported., Results: The mean age was 76.9 ± 10.4 years, and Society of Thoracic Surgeons predicted risk score averaged 5.2 ± 3.4%. One-year overall mortality and stroke rates were 18.2% and 2.4%, respectively. Quality-of-life index improved from baseline to 30 days and at 1 year (p < 0.001 for both). Mild paravalvular aortic regurgitation occurred in 21.7% of patients, while moderate or greater paravalvular aortic regurgitation occurred in 4.3%. Mild and moderate or severe transvalvular aortic regurgitation occurred in 11.6% and 0%, respectively. Valve gradients remained stable at 1 year., Conclusions: S3 TAVR in annular areas >683 mm2 is feasible, with favorable mid-term outcomes., (Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
7. Impact of Chronic Kidney Disease on Decision Making and Management in Transcatheter Aortic Valve Interventions.
- Author
-
Hensey M, Murdoch DJ, Sathananthan J, Wood DA, and Webb JG
- Subjects
- Aortic Valve Stenosis complications, Humans, Risk Factors, Aortic Valve surgery, Aortic Valve Stenosis surgery, Decision Making, Heart Valve Prosthesis, Practice Guidelines as Topic, Renal Insufficiency, Chronic complications, Transcatheter Aortic Valve Replacement methods
- Abstract
The coexistence of chronic kidney disease (CKD) and severe aortic stenosis (AS) is common, and the prevalence of both is rising. The 2 conditions are inherently linked in that significant CKD may accelerate the development of AS and severe AS may result in deteriorating kidney function. The volume of and indications for transcatheter aortic valve implantation (TAVI) procedures are ever-increasing, and there are many challenges that need to be considered in patients with concomitant severe AS and CKD being assessed for TAVI. Throughout the process of working these patients up for definitive management of their valvular heart disease, the presence of CKD impacts on diagnostic investigations, treatment decisions, and therapeutic interventions. Herein we review the current literature regarding TAVI in patients with CKD focusing on the decision-making process and specific risks involved in TAVI and CKD. We also provide specific practical strategies to best manage this challenging patient cohort., (Crown Copyright © 2018. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
8. Early experience with a purpose-designed temporary pacing guidewire for transcatheter valve implantation.
- Author
-
Hensey M, Daniels D, Wood D, and Webb JG
- Subjects
- Aortic Valve Stenosis diagnosis, Aortic Valve Stenosis physiopathology, Humans, Treatment Outcome, Ventricular Function, Left, Aortic Valve Stenosis therapy, Cardiac Pacing, Artificial methods, Heart Valve Prosthesis Implantation methods, Transcatheter Aortic Valve Replacement methods
- Published
- 2019
- Full Text
- View/download PDF
9. Transcatheter Valves Get More Complicated.
- Author
-
Webb JG and Hensey M
- Subjects
- Aortic Valve surgery, Humans, Treatment Outcome, Aortic Valve Stenosis surgery, Lacerations, Transcatheter Aortic Valve Replacement
- Published
- 2019
- Full Text
- View/download PDF
10. Transcatheter Aortic-Valve Replacement - 10 Years Later.
- Author
-
Murdoch DJ, Webb JG, Ye J, Sathananthan J, Hensey M, Wood DA, Cheung A, Leipsic J, Blanke P, and Lauck S
- Subjects
- Aged, Aortic Diseases complications, Aortic Valve diagnostic imaging, Aortic Valve surgery, Aortic Valve Stenosis complications, Aortic Valve Stenosis diagnostic imaging, Female, Heart Failure etiology, Humans, Tomography, X-Ray Computed, Treatment Outcome, Vascular Calcification complications, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement
- Published
- 2019
- Full Text
- View/download PDF
11. TAVR and SAVR in ESRD: Just because we can doesn't necessarily mean that we should.
- Author
-
Hensey M and Webb JG
- Subjects
- Aortic Valve surgery, Humans, Risk Factors, Treatment Outcome, Aortic Valve Stenosis surgery, Heart Valve Prosthesis Implantation, Kidney Failure, Chronic, Transcatheter Aortic Valve Replacement
- Abstract
In patients with end stage renal disease on hemodialysis, TAVR resulted in reduced length of stay, hospitalization cost, complication rate and higher rates of home discharge compared to SAVR. In-hospital mortality and complication rates were high in both groups. Careful patient selection and further research is required to identify patients with end-stage renal disease who might, or might not, benefit from intervention., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.